Webinar
Considerations for Drug Expansions under the Medicare Drug Price Negotiation Program
calendar

March 3, 2025

Calendar
clock

9:30am - 11:00am

(GMT-05:00)

Register

View all IQVIA events

The Inflation Reduction Act’s Medicare Drug Price Negotiation Program represents a paradigm shift in drug pricing policy in the U.S. For drugs selected for maximum fair price (MFP) setting, the window for achieving returns is likely to condense as the MFP setting comes into effect at 9 years post-initial FDA approval for small molecules and 13 years for biologics. This changing dynamic suggests that clinical development post-initial approval may be adversely impacted. Understanding the historical trends in this development is crucial for assessing the potential effects of this policy on innovation and implications for stakeholders.

The IQVIA Institute for Human Data Science is convening a multidisciplinary webinar to discuss the drug lifecycle, post-approval expansions, and the impacts of the IRA’s Price Negotiations Program on the future of innovation.

Key topics for discussion will include:

  • The current/historical state of the drug lifetime journey and value of expansions post-initial approval
  • Potential impacts of the IRA’s Price Negotiations Program on drug development, incentives, and patient outcomes
  • Implications for the future and the path ahead for ensuring continued proliferation of innovation
  • Speakers in the webinar will include representatives from different stakeholders to represent perspectives of manufacturers, payers, and patients.

Who Should Attend

  • U.S. Policymakers
  • U.S. Government
  • Pharmaceutical and Biotech Industry
  • Clinical/R&D Leaders
  • Others in Life Sciences

Related solutions

Contact Us